Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure (TC-002-301)

Prospective, double-masked, randomized, multi-center, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TearClear latanoprost Ophthalmic Solution, 0.005% (TC-002) compared to latanoprost Ophthalmic Solution, 0.005% (LAT) in subjects with elevated intraocular pressure at approximately 20 study sites located in the United States

Study Overview

• Status: Active, not recruiting
• Conditions: Elevated Intraocular Pressure
• Intervention / Treatment: Drug: Latanoprost ophthalmic solution, 0.005%; Drug: TC-002 latanoprost ophthalmic solution, 0.005%

Detailed Description

This is a Phase 3, randomized, investigator-masked, multicenter, parallel-group trial comparing two ophthalmic solution formulations of latanoprost at a fixed dose of 0.005% administered once daily (QD) for 12 weeks.

Approximately 300 subjects will be randomized in this study at approximately 20 sites in the United States (US).

Treatment assignments will be masked to TearClear, study subjects, Investigators and site staff. Because the container closure for the investigational product is different, this study will use an unmasked dosing coordinator at each study site. All clinical trial supplies will be masked by using carton boxes to mask the appearance of the immediate container closure.

At approximately 2 select sites, approximately10% of total randomized subjects will have systemic PK labs drawn.

The study involves 7 clinic visits, including Screening (Visit 1), Randomization (Visit 2) and treatment visits (Visits 3, 5 and 7, during which ophthalmic assessments will occur and IOP will be assessed diurnally. There will be two interim IP dispensation visits (Visits 4 and 6).

• Study Type: Interventional
• Enrollment (Anticipated): 300
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • California
    • Garden Grove, California, United States, 92843
      • Orange County Ophthalmology Medical Group
    • Glendale, California, United States, 91204
      • Global Research Management
    • Mission Hills, California, United States, 91345
      • North Valley Eye Medical Group
    • Newport Beach, California, United States, 92663
      • Eye Research Foundation
    • Petaluma, California, United States, 94954
      • North Bay Eye Associates
    • Rancho Cordova, California, United States, 95670
      • Martel Eye Medical Group
    • Torrance, California, United States, 90505
      • Wolstan & Goldberg Eye Associates
    • Westminster, California, United States, 92683
      • Michael K. Tran, MD
  • Florida
    • Delray Beach, Florida, United States, 33484
      • Segal Drug Trials
    • Largo, Florida, United States, 33773
      • Shettle Eye Research Inc.
    • Tampa, Florida, United States, 33603
      • International Research Center
  • Kentucky
    • Louisville, Kentucky, United States, 40206
      • The Eyecare Institute/Butcherton Clinical Trials
  • New York
    • Rochester, New York, United States, 14618
      • Rochester Ophthalmological Group PA
  • Ohio
    • Cleveland, Ohio, United States, 44115
      • Abrams Eye Center
  • Pennsylvania
    • Cranberry Township, Pennsylvania, United States, 16066
      • Scott & Christie Associates PC
  • Tennessee
    • Memphis, Tennessee, United States, 38119
      • Total Eye Care P.A.
  • Texas
    • El Paso, Texas, United States, 79902
      • Louis M. Alpern, M.D., M.P.H., P.A.
    • Houston, Texas, United States, 77008
      • Houston Eye Associates
    • San Antonio, Texas, United States, 78238
      • San Antonio Eye Center
    • San Antonio, Texas, United States, 78229
      • R&R Research LLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Greater than 18 years old.
2. Have been diagnosed and treated for bilateral open-angle glaucoma or ocular hypertension in both eyes.
3. Currently and for at least 30 days prior to screening, are being treated with a stable dose of latanoprost ophthalmic solution or prostaglandin analog for which there is a documented and positive treatment response with either agent maintained within both eyes.
4. Have best corrected visual acuity (BCVA) via Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) score +0.6 logarithm of the minimum angle of resolution (logMAR) or better in each eye.
5. At Visit 1, have IOP on prostaglandin or prostaglandin analog single therapy ≤ 21mmHg, at Visit 2, have diurnal IOP between 22 and 30 mmHG, inclusive for each eye.
6. In the Investigator's judgment, are able to safely discontinue current ocular hypotensive medication during the washout period.
7. Willing and able to avoid wearing contact lenses from Visit 1 (Screening) and for the duration of the trial.
8. Willing and able to self-administer or have an able person available on a daily basis to assist with administration of study medication.
9. Female subjects must either be incapable of pregnancy because of bilateral oophorectomy, hysterectomy, or bilateral tubal ligation, or be post-menopausal (have been amenorrheic for at least 2 years) or must use an effective (e.g., double-barrier) method of birth control for the duration of the study. Female subjects of childbearing potential must have a negative pregnancy test and not be nursing.
10. Willing and able to comply with all study procedures.

Exclusion Criteria:

1. Causes of glaucoma other than primary open-angle glaucoma, including:

   1. narrow angles (3 quadrants with less than Grade 2 according to Shaffer anterior chamber angle grading system) and subjects with angle closure
   2. clinically significant peripheral anterior synechiae
   3. congenital glaucoma
   4. a history of angle closure in either eye
   5. aphakic glaucoma
   6. traumatic glaucoma
   7. neovascular glaucoma
   8. pigmentary glaucoma
   9. pseudoexfoliative glaucoma
   10. drug-induced glaucoma
2. Using a multi-drop treatment (other than prostaglandin or prostaglandin analog) for IOP-lowering medications.
3. Advanced glaucoma or subjects with a cup/disc ratio greater than 0.8.
4. Have undergone incisional IOP-lowering surgeries a placement or removal of minimally invasive glaucoma implant (MIG) in either eye.
5. Have undergone non-incisional IOP-lowering surgeries within the past 6 months.
6. Used anti-vascular endothelial growth factor (anti-VEGF) within 12 months of screening.
7. Used intraocular, periocular or topical corticosteroids within 60 days of screening.
8. Have received laser surgery for glaucoma (selective laser trabeculoplasty [SLT] or argon laser trabeculoplasty [ALT]) within 6 months of screening.
9. Have uveitis, iritis or congenital aphakia.
10. Are unwilling to discontinue current glaucoma medication within 30 days of the randomization (Visit 2).
11. Have had intraocular or periocular surgery within the past 3 months.
12. Are non-responsive to topical prostaglandins, prostamides or prostaglandin analogs in the Investigator's judgement.
13. History of previous complicated cataract surgery, or previous refractive keratotomy in either eye.
14. Used miotics and oral/topical carbonic anhydrase inhibitors within 5 days of screening.
15. Have any known hypersensitivity to any components of the formulation or latanoprost.
16. Have participated in a clinical trial for IOP-lowering investigational product or exposure to an IP within the prior 30 days.
17. In the judgement of the Investigator, have previous or currently active clinically significant systemic or ocular disease in either eye that could affect study outcome.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: LAT, 0.005%; Commercially available FDA-approved generic latanoprost ophthalmic solution, 0.005%	Drug: Latanoprost ophthalmic solution, 0.005%; Commercially available, FDA-approved generic latanoprost ophthalmic solution, 0.005% (LAT) without modification will be used as the active control
Experimental: TC-002; TC-002, TearClear latanoprost ophthalmic solution, 0.005%	Drug: TC-002 latanoprost ophthalmic solution, 0.005%; TC-002 is formulated using the commercially available latanoprost drug substance; delivered drop to the eye is preservative-free.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Primary efficacy endpoint is the difference in mean change from baseline (CFB) in IOP	Weeks 2, 6, and 12 at 8:00 AM, 10:00 AM, and 4:00 PM.

Secondary Outcome Measures

Outcome Measure	Time Frame
Secondary efficacy endpoints include diurnal (average of 8:00 AM, 10:00 AM, and 4:00 PM measurements) IOP	Weeks 2, 6, and 12.

Collaborators and Investigators

• Sponsor: TearClear Corp

Study record dates

Study Major Dates

• Study Start (Actual): November 29, 2021
• Primary Completion (Anticipated): September 1, 2022
• Study Completion (Anticipated): September 1, 2022

Study Registration Dates

• First Submitted: December 17, 2021
• First Submitted That Met QC Criteria: December 17, 2021
• First Posted (Actual): December 21, 2021

Study Record Updates

• Last Update Posted (Actual): May 25, 2022
• Last Update Submitted That Met QC Criteria: May 23, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Keywords: open-angle glaucoma; ocular hypertension; elevated IOP
• Additional Relevant MeSH Terms: Eye Diseases; Ocular Hypertension; Ophthalmic Solutions; Pharmaceutical Solutions; Latanoprost
• Other Study ID Numbers: TC-002-301

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No